Background: Risankizumab (RZB) is a safe and effective treatment for Crohn’s disease (CD). The phase 3b SEQUENCE study directly compared the efficacy and safety of RZB, a selective IL-23 p19 inhibitor, and ustekinumab (UST), an IL-12/IL-23 p40 inhibitor. Methods:
Meeting Materials
Background:
Background: We evaluated icanbelimod, a selective small-molecule sphingosine-1-phosphate-1 (S1P1) receptor modulator, as induction and maintenance therapy for moderately to severely active ulcerative colitis (UC). Methods:
Background:
Background:
Background:
Background: Risankizumab (RZB), a monoclonal antibody neutralizing interleukin (IL)-23p19, was evaluated for efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC) in the phase 3 trial, INSPIRE (NCT03398148). Methods:
Background: Recombinant zoster vaccine (RZV) has been shown to reduce the short-term risk of herpes zoster (HZ) in patients with inflammatory bowel disease (IBD). However, there is lack of data regarding the long-term efficacy in this population. Methods:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background: There are few data on the quality-of-care for inflammatory bowel disease (IBD) in public, private or mixed hospitals. Aim: To evaluated clinic and quality parameters and their association with need for ICU and death in Brazilian hospitals. Methods:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background: There is limited data specifically for patients with anemia and Chron’s disease (CD). We sought to examine the national inpatient sample database to describe in-hospital outcomes among these individuals. Methods:
Background:
Background:
Background:
Background: Fatigue in Crohn’s disease (CD) is debilitating and costly for the patient and healthcare system. It does not have well-established therapies, and it is important to investigate risk factors and, therefore, collaborate to prevent or reduce symptoms.
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Female patient, 28 years old, diagnosed with ulcerative colitis 3 years ago, being treated with mesalazine 3.2g/day. She reports worsening of the condition with bloody mucous diarrhea, and azathioprine 150 mg/day was introduced without improvement.
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background: Inflammatory bowel diseases (IBDs) are an increasing burden for societies. We examined Polish Social Insurance Institution (ZUS) work incapacity expenditures for people with IBD compared with the general population. Methods:
Background:
Background: There is limited data specifically for patients with upper extremity deep venous thrombosis (UEDVT) and Ulcerative Colitis. We sought to examine the national inpatient sample database to describe in-hospital outcomes among those patients. Methods:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background: The simultaneous use of immunobiologicals is a non-standard therapeutic option for cases of refractory inflammatory bowel disease (IBD). The objective of the study is to present three cases of Crohn’s Disease (CD) treated with a combination of immunobiologicals.
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background:
Background: Metastatic Crohn’s disease (MCD), defined as skin lesions present in areas noncontiguous with the gastrointestinal tract, is the rarest cutaneous manifestation of Crohn’s disease. MCD lesions vary in morphology and can arise anywhere on the skin.
Background:
Background: There are limited data specifically for female patient with Chron’s disease (CD). We sought to examine the national inpatient sample database to describe in-hospital outcomes among these individuals. Methods:
Background:
<p>Background: Crohn’s disease (CD) can affect any segment of the gastrointestinal tract (GIT), often requiring a combination of medical and surgical treatment. Economical resections are generally recommended, whether intestinal or perianal/perineal.
Background:
Background:
Background:
Background:
Background:
S1
Background:
Background:
S1
Background:
Background:
S2
Background:
Background:
S3
Background:
Background:
S3
Background:
S1
Background:
S3
Background:
S2
Background:
S4
Background:
S2
Background:
S4
Background:
S2
Background:
S5
Background: Little is known about IBD outcomes in transgender and gender nonconforming (TGNC) patients receiving gender-affirming hormone (GAH) therapy. The aim of this study was to compare IBD outcomes in the year before and after GAH initiation. Methods:
S4
Background:
S6
Background: Ozanimod (OZA) is an oral, selective sphingosine 1-phosphate receptor 1 and 5 modulator approved for the treatment of moderately to severely active ulcerative colitis (UC) in adults. This study evaluates the efficacy and safety of OZA in real-world clinical practice.
S4
Background:
S7
Background:
S5
Background:
S8
Background:
S5
Background:
S8
Background:
S6
Background:
S8
Background:
S6
Background:
S9
Background:
S6
Background:
S9
Background:
S7
Background:
S9
Background:
S7
Background:
S10
Background:
S8
Background:
S10
Background:
S9
Background:
S10
Background:
S10
Background:
S11
Background: Patients with chronic diseases often seek health information and self-management tools. It is not known the type of self-help tools that patients with IBD prefer to use, how the tools are used, and the challenges they encounter with self-help tools. Methods:
S11
Background:
S11
Background:
S11
Background:
S12
Background:
S12
Background:
S12
Background:
S13
Background:
S13
Background:
S13
Background:
S14
Background:
S14
Background:
S14
Background:
S14
Background:
S15
Background:
S15
Background:
S17
Background:
S15
Background:
S17
Background:
S16
Background:
S17
Background:
S16
Background: Sarcopenia is a progressive pathological condition which can present in inflammatory bowel disease (IBD) together with changes in body composition. Aim. To provide ultrasound assessment of muscle mass and bioimpedance analysis of body composition in patients with IBD.
S18
Background: The inflammatory bowel disease (IBD) navigation program represents a significant advancement in the approach to these complex conditions. This study aims to report on the implementation of an IBD navigation program in a private IBD referral center in Brazil. Methods:
S16
Background:
S19
Background:
S16
Background:
S20
Background: Ozanimod, a selective sphingosine 1-phosphate receptor modulator, is approved for the treatment of moderately to severely active ulcerative colitis (UC) in the United States and European Union and is being studied for use in Japan. Methods:
S17
Background:
S20
Background:
S18
Background:
S21
Background:
S18
Background:
S21
Background:
S18
Background:
S22
Background:
S19
Background:
S23
Background:
S19
Background:
S23
Background:
S20
Background:
S24
Background:
S20
Background:
S24
Background:
S21
Background:
S24
Background:
S22
Background:
S25
Background:
S22
Background:
S25
Background:
S22
Background:
S25
Background:
S23
Background:
S26
Background:
S23
Background:
S26
Background: The purpose was to assess the quality and readability of online information regarding J-pouch surgery across academic, commercial, and foundation/advocacy websites. Methods:
S24
Background:
S27
Background:
S25
Background:
S27
Background:
S26
Background:
S27
Background:
S26
Background:
S28
Background:
S28
Background:
S28
Background:
S28
Background:
S28
Background:
S29
Background:
S29
Background:
S29
Background:
S31
Background:
S29
Background:
S31
Background:
S30
Background:
S31
Background:
S30
Background:
S31
Background:
S30
Background:
S32
Background:
S32
Background:
S32
Background:
S32
Background:
S33
Background:
S33
Background:
S12
Background: A combination of curcumin and QingDai (CurQD) was shown to be effective in ulcerative colitis but its benefit in Crohn’s disease (CD) has not been studied. Methods:
S13
Background:
S21
Background: Patients with ulcerative colitis (UC) are at an increased risk of UC-associated neoplasia (UCAN). Endoscopic submucosal dissection (ESD) is an acceptable treatment option for patients with UCAN. This study aimed to evaluate the feasibility of ESD for UCAN. Methods:
S27
Background:
